Positive results from the confirmatory phase 3 clinical trial removes a major overhang on Eisai. The company plans to submit marketing approval for the drug in the US, EU, and Japan by FY23.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.